Mogamulizumab, designated as KW-0761 and bearing the compound code 1159266-37-1, represents a unique approach to treating cutaneous T-cell lymphoma (CTCL). This engineered monoclonal immunoglobulin selectively targets https://www.targetmol.com/compound/mogamulizumab